Blog

BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq:GNLN), a Berachain-focused digital asset treasury company and global seller of premium cannabis accessories, and subsequent to the Company’s press releases issued on October 24, 2025 and November 14, 2025 that disclosed Greenlane’s Berachain cryptocurrency treasury strategy (the “Berachain Treasury Strategy”), is providing an update on its BERA token holdings, staking activity, and capital position related to its participation in the Berachain ecosystem.

The Company commenced its Berachain Treasury Strategy on October 23, 2025. Between October 23 and December 3, 2025, Greenlane purchased $8 million of BERA, expanding its BERA holdings by approximately 5.76 million BERA at an average purchase price of approximately $1.39 per BERA.

The Company has staked substantially all of approximately 8.33 million BERA, representing the liquid on-chain portion of its 60.17 million BERA position¹. The remainder of the BERA tokens remain subject to lock up or vesting. As of December 8, 2025, Greenlane has earned over 180,000 BERAfrom staking since launching the Berachain Treasury Strategy. The annualized percentage return of Berachain’s Proof of Liquidity (“PoL”) staking on December 3, 2025 was 30%², subject to prevailing network conditions³.

As of December 3, 2025, the Company had approximately 32 million dollars of U.S. dollar cash and dollar pegged stablecoin reserves allocated to the Berachain Treasury Strategy⁴. Purely for illustrative purposes, if BERA tokens were available at $1.00 per token and assuming no impact from the Company’s own purchases on market prices, that cash would equate to approximately 31 million BERA, or roughly 23% of the estimated circulating supply as of December 3, 2025, based on data from CoinMarketCap. There is no assurance that such tokens would be available at those prices or in those quantities.

“I believe that we have maintained a disciplined investment approach throughout a volatile cryptocurrency market. We retain the vast majority of the net proceeds from our recent private investment, which puts us in a strong position to continue building out our BERA treasury and yield generation strategies over the remainder of 2025 and into 2026,” said Ben Isenberg, Chief Investment Officer.

Greenlane expects to continue purchasing BERA during the fourth quarter of 2025, with plans to deploy into PoL staking and/or decentralized finance venues across the Berachain ecosystem to generate additional revenues.

About Greenlane

Greenlane is a global platform for the development and distribution of premium smoking accessories, vape devices, and lifestyle products to thousands of producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. In October 2025, Greenlane initiated a Berachain treasury strategy dedicated to acquiring BERA and increasing BERA-per-share through active management of the Company’s treasury. The Company is a Berachain ecosystem participant focused on supporting the development and operation of blockchain-based infrastructure, including assets and applications built on Berachain. The Company engages in network staking, liquidity provisioning, and strategic initiatives intended to contribute to the long-term sustainability of decentralized protocols within its portfolio.

About Berachain

Berachain (BERA) is the first blockchain powered by Proof of Liquidity, designed to help businesses scale and provide sustainable on-chain economies. Proof of Liquidity provides BERA with a staking yield derived from the revenues or ownership of profitable, revenue-generating companies building on the network. Berachain has raised $150M from leading digital asset investors including Brevan Howard, Framework Ventures, Polychain Capital, Samsung Next, Laser Digital by Nomura, Goldentree Asset Management, SBI VC Trade and more.

Media Contacts:

Greenlane Holdings, Inc.
Investor Contact:
IR@greenlane.com

or

PCG Advisory
Kevin McGrath
+1-646-418-7002

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are statements other than historical facts and include, without limitation, statements regarding progress and achievement of the Company’s goals regarding BERA acquisition and staking, the long-term value of BERA, continued growth and advancement of the Company’s Berachain Treasury Strategy and the applicable benefits to the Company, and other projections or statements of plans and objectives.

These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, the Company’s ability to execute its growth strategy; its ability to raise and deploy capital effectively; developments in technology and the competitive landscape; changes in the regulatory landscape applicable to digital assets, including BERA; the market performance of BERA; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on November 14, 2025 and in other subsequent filings with the SEC. These filings are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Cautionary Note Regarding Digital Assets

BERA is a digital asset that is not legal tender, is not backed by any government or central bank and may be subject to extreme price volatility, regulatory uncertainty and technological risk. Investments in and exposures to digital assets such as BERA are highly speculative and may result in the loss of all or a substantial portion of the invested capital. The Company’s activities involving BERA and other digital assets may not be suitable for all investors and are subject to the risks described in the “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on November 14, 2025 and in other subsequent filings with the SEC. These filings are available at www.sec.gov.

¹ Current 60.17 million BERA holding is comprised of (i) initial BERA holding of 54.23 million BERA, per Greenlane press release dated October 24, 2025, (ii) 5.76 million BERA purchased, and (iii) 0.18 million BERA earned from staking.

² Annualized protocol rate calculated using weekly data, “return” refers to protocol rewards measured in BERA units (i.e. a 30% annualized return on 100 BERA is 30 BERA). A quoted rate of return is a point-in-time protocol figure. Reward and return metrics can fluctuate rapidly, and should not be viewed as indicative of future results or as any guarantee of future performance. The current and historical annualized rates of return may be viewed at any point on https://hub.berachain.com/stake/

³ Prevailing network conditions include, but may not be limited to, protocol parameter changes, reward schedule adjustments, validator set changes and market volatility.

⁴ Per Greenlane press release dated October 24, 2025, the Company raised gross proceeds of $50 million in closed Private Investment in Public Entity Financing, or 43 million dollars in U.S. dollar cash and dollar-pegged stablecoins, net of transaction fees. Less approximately $3 million in cash used by the Company’s legacy business and approximately $8 million used to purchase BERA between October 23 and December 3, 2025, leaving approximately 32 million dollars of U.S. dollar cash and dollar-pegged stablecoins remaining, allocated to the Berachain Treasury Strategy.

SOURCE: Greenlane Holdings, Inc.

View the original press release on ACCESS Newswire

New data presented at the 2025 ASH demonstrates 94% disease free and overall survival rate

Omisirge approved by FDA as First Cell Therapy to Treat Severe Aplastic Anemia

Key Highlights of Data Presented at ASH:

• 95% of patients achieved rapid neutrophil recovery

• Median time to neutrophil recovery: 8 days

• Immune recovery post-transplant was rapid

• 94% disease-free and overall survival

• No cases of BMT-CTN severe acute graft-versus-host disease (GVHD), or chronic GVHD observed

• Omisirge approved by the FDA on December 5, 2025 for SAA

DUBLIN, IRELAND AND LONDON, UK = / ACCESS Newswire / December 8, 2025 / Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a leader in cell therapy innovation today announced further positive interim clinical results for Omisirge (Omidubicel-onlv), its advanced stem cell transplant therapy for Severe Aplastic Anemia (SAA). The data were presented by Dr. George Aue of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), at the American Society of Hematology (ASH) 2025 Annual Meeting, taking place from Dec 6-9 in Orlando FL.

The ongoing open-label, single-center study (NCT03173937|17-H-0091), led by Dr. Richard Childs of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), demonstrated highly encouraging results. Among 19 patients (median age 20 years) whose disease had not responded to standard therapies, 18 (95%) achieved rapid neutrophil recovery with a median time of 8 days. Both disease-free survival and overall survival were 94%. Importantly, only 16% of patients experienced (BMT-CTN Grade II) acute GvHD and no cases of severe (BMT-CTN Grade III-IV) acute GVHD or chronic GVHD were observed.

Dr. Richard Childs of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) commented: “The results of the ongoing study are extremely encouraging and indicate a significant advancement in the treatment options for patients with a high unmet medical need. The SAA patients in the study were high risk but had significantly better than expected outcomes with remarkably fast and high rates of neutrophil engraftment. This was achieved with low rates of mild acute GVHD and no chronic GVHD, meaning patients experienced a rapid return to normal life.”

Dr. Ronit Simantov, Chief Medical and Scientific Officer of Ayrmid commented: “These results highlight the significant potential of Omisirge as a transplant option for patients with SAA given the rapid and sustained recovery of blood counts observed. Omisirge potentially expands transplant access for patients who otherwise have limited options. We remain deeply committed to advancing transformative therapies for patients with serious unmet medical needs.”

Omisirge is now approved for treatment in adults and pediatric patients 6 years of age and older with SAA following reduced intensity conditioning. The FDA approval of Omisirge was based on data from the 17-H-0091 study.

About Severe Aplastic Anemia

Severe Aplastic Anemia is a rare, life-threatening hematologic disorder in which the bone marrow fails to produce sufficient blood cells. Stem cell transplantation offers a potential cure; however, many patients lack a matched sibling donor. Ayrmid is advancing therapies to address this unmet medical need.

About Ayrmid Ltd. and Gamida Cell

Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge (please see the current full Prescribing Information, including boxed warning, here) and APHEXDA^® (please see the current full Prescribing Information here). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook or Instagram.

Contacts: Media, Investors / Business Development: bd@ayrmid.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Ayrmid Pharma Ltd

View the original press release on ACCESS Newswire

• Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy‘s cash price

• Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors

• Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience

• Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders

TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the “Wellgistics Pharmacy Network”) that primarily target patients in rural communities where there is often an increased incidence of diabetes. The launch is targeting the 33 million Americans who have been diagnosed with type II diabetes^[1] and whose out-of-pocket costs for SGLT-2 drugs exceed the Brenzavvy cash price.

Jardiance® and other SGLT-2 inhibitor drugs reached sales of $16.8 billion in 2024, with projected growth projected to reach $28.9 billion by 2033. The United States represents 40.8% of that market according to Grandview Research^[2]. A large scale analysis of data from 28 US health systems in 2022-2023 showed that guideline-recommended prescription of SGLT-2 inhibitors in diabetics with a class 1A recommendation is only 11.9%^[3], leading to suboptimal care for the vast majority of such patients. As the Company’s proprietary EinsteinRx artificial intelligence pharmacy platform is being rolled out into the Wellgistics Pharmacy Network’s point-of-sales systems, Wellgistics will alert pharmacists to patients with a likely class 1A recommendation for a SGLT-2 inhibitor, as well as the likely patient benefit from dispensing Brenzavvy vs. other SGLT-2 inhibitors in the majority of cases where such a class 1A recommendation does not exist. Once alerted, pharmacists will be able to work to rapidly educate the provider on the benefits of Brenzavvy vs. other SGLT-2 inhibitors in patients without cardiovascular disease or chronic kidney disease (CKD). Brenzavvy’s competitive price point when compared with the out-of-pocket costs of Jardiance & other SGLT-2 inhibitors, provides a compelling rationale for pharmacist-driven education of providers to help optimize prescribing decisions and help improve patient access.

“By rapidly helping providers optimize therapy selection for patients without delaying dispensing timelines, pharmacists are uniquely positioned to help drive better outcomes for their patients without increasing out-of-pocket costs,” said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. “Pharmacists are one of the most trusted sources of information about how prescription drugs will impact the health of patients, especially in rural communities. EinsteinRx is empowering these trusted healthcare professionals with the advanced technology they need to get the right drug to the right patient at the right time. With the launch of Brenzavvy through our Wellgistics Pharmacy Network, we can provide remuneration opportunities for both products and services, with the latter helping pharmacists improve their ROI by educating providers on the patient-specific advantages of Brenzavvy. We believe that this pharmacist-led provider education model will enable the blueprint for other later-generation drugs with similar product profile advantages to rapidly establish market share.”

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the “Wellgistics Pharmacy Network”) and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties’ plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.’s and Wellgistics Health, Inc.’s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

Wellgistics Investor Relations Contact

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / December 8, 2025 / Gold has always been a trusted store of value, but the systems that track it have never matched its economic importance. Every year more than 1,100 tons of recycled gold move through global markets. Yet provenance often relies on paper documentation, fragmented logistics, and reputation instead of measurable proof. Goldstrom’s collaboration with SMX (NASDAQ:SMX) highlights how quickly that old framework is disappearing. The moment gold carries a molecular identity, the market stops operating on assumptions and starts operating on verification.

Goldstrom is part of a much larger shift. Global hubs like DMCC handle enormous volumes of precious metals, and they face the same challenge. They need infrastructure that can verify material origin, confirm recycled content, and prove chain-of-custody integrity with accuracy that approaches 100%. SMX provides that layer. It upgrades gold from a passive commodity into an identity-backed asset. Fraud exposure, historically estimated at 2% to 5% in some bullion channels, becomes preventable. Every transaction becomes accountable.

The value difference is measurable. Traders can begin pricing verified metals separately from unverified inventory. Refineries can certify recovered gold without depending on declarations. Regulatory bodies can enforce responsible sourcing without slowing global trade. Even a modest 1% premium on fully verifiable gold creates billions in incremental market value across the ecosystem. That is what happens when materials have memory. Identity is not a label. It is a new economic variable.

Following The Path of Circularity

Circularity gains move in parallel. The gold recycling industry loses between 10% and 15% of potential value, not because of inefficiency in recovery, but because of uncertainty in documentation. When recycled gold cannot be proven, it gets discounted. When it can be proven, it becomes preferred feedstock. Goldstrom’s work with SMX demonstrates how quickly those losses can be reversed. Verified recycled metals trade on evidence, not trust. That helps redirect large volumes of secondary gold away from discount channels and back into certified high-grade supply. Circularity becomes a competitive advantage instead of a compliance checkbox.

DMCC’s position makes this even more consequential. As one of the world’s most influential trading corridors, DMCC sits at the center of global bullion flows. Its participants need clarity, speed, and confidence across cross-border movements. Identity-backed verification enables exactly that. Regulators can strengthen oversight without friction. Traders can reduce counterparty risk. Markets respond with stronger liquidity and more accurate pricing.

What once required manual auditing becomes automated and measurable.

Sector Shift is Shining Bright

This is why the precious-metals sector is shifting from partnership stories to infrastructure stories. The moment verification becomes technical rather than subjective, the market recalibrates. Risk declines. Transparency increases. Circular supply chains expand. Institutions that manage billions in metals can finally apply the same standards of accountability used in financial securities. The trust economy gets replaced by the proof economy.

Goldstrom showcases the upstream transformation. DMCC showcases the downstream transformation. SMX provides the connective fabric between them. As identity-backed gold becomes the norm, the global market will not move gradually. It will reprice itself. The assets that can prove their history will command the confidence premium. The assets that cannot will trade at a discount.

Gold has waited centuries for a verification layer worthy of its value. It just received it. From SMX.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber, plastic and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

Tonight’s show is sponsored by commercials from Laser Photonics, DataVault, Aeries Technology, Sustainable Green Team, PetVivo, and Synergy CHC

NEW YORK CITY, NEW YORK / ACCESS Newswire / December 6, 2025 / New to The Street, one of the nation’s most established and fastest-growing financial news and sponsored-programming platforms, announces tonight’s nationwide television broadcast on Bloomberg Television at 6:30 PM EST. The episode features executive interviews with Roadzen (NASDAQ:RDZN), BioVie (NASDAQ:BIVI), and TY J Young Wealth, offering viewers cutting-edge insights across AI mobility, biotech innovation, and strategic wealth management.

---

Featured Interviews on Tonight’s Broadcast

Roadzen (NASDAQ:RDZN)
A deep dive into Roadzen’s AI-powered auto insurance platform and the company’s global expansion initiatives redefining mobility risk intelligence.

BioVie (NASDAQ:BIVI)
An update on the company’s advancing clinical programs targeting neurological and liver-related diseases, with insight into upcoming milestones.

TY J Young Wealth
A segment focused on wealth-building frameworks, financial strategy, and guidance for investors preparing for 2026 market conditions.

---

Show Sponsors

Tonight’s broadcast is made possible through commercial sponsorships from leading innovators across multiple industries:

• Laser Photonics (NASDAQ:LASE)

• DataVault Holdings (NASDAQ:DVLT)

• Aeries Technology (NASDAQ:AERT)

• The Sustainable Green Team (OTCQX:SGTM)

• PetVivo Holdings

• TY J Young Wealth

• Synergy CHC (NASDAQ:SNYR)

These sponsors support New to The Street’s mission of providing unmatched national visibility for public companies through television, digital distribution, and outdoor media.

---

About New to The Street

New to The Street, produced by FMW Media, is one of America’s longest-running and most influential financial television brands, approaching its 17th anniversary. The platform broadcasts sponsored programming on Bloomberg Television and Fox Business, with additional distribution across digital networks and outdoor media in Times Square and the New York City Financial District.

With 4 million subscribers across the New to The Street TV YouTube channel and more than 800,000 followers across X, Facebook, LinkedIn, and Instagram, the brand delivers one of the largest combined digital and social financial audiences in the United States. This ecosystem-supported by high-impact television, online video, earned media, and iconic billboard placements-provides companies with unmatched reach and credibility across the investor community.

Media Contact; Monica@NewtoTheStreet.com

SOURCE: New to The Street

View the original press release on ACCESS Newswire

Key Highlights

• Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies

• 90% (9 of 10) of patients were able to collect sufficient HSC to enable progress to gene therapy manufacturing

• 86% (6 of 7) of patients had previously failed to collect sufficient cells with plerixafor

• Results support the use of motixafortide as an effective single-agent mobilizer of HSC for people with sickle cell disease for gene therapies

• Findings presented at ASH 2025

LONDON, UK / ACCESS Newswire / December 6, 2025 / Ayrmid, Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., today announced encouraging real-world data on the use of motixafortide, a long-acting CXCR4 inhibitor licensed by Ayrmid under the brand name APHEXDA^®, for mobilizing HSCs in patients with sickle cell disease undergoing gene therapy. The results were presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place from Dec 6-9 in Orlando FL.

Motixafortide is currently FDA approved in combination with filgrastim (G-CSF) for stem cell mobilization in multiple myeloma. The product’s effectiveness and pharmacologic profile have prompted growing interest in its potential use for sickle cell disease, where collecting adequate stem cells remains a significant barrier to gene therapy. Many patients do not mobilize enough cells with standard approaches, limiting access to curative treatment.

Researchers from five treatment centers evaluated the real-world use of motixafortide in ten patients aged 14-50. Each patient underwent one or more collection cycles over two or more days to obtain the number of stem cells required for gene therapy manufacturing.

Among the seven patients who previously failed plerixafor, motixafortide led to a substantial improvement in stem cell mobilization, enabling six of the seven to successfully collect enough cells to progress to gene therapy manufacturing. Manufacturing or infusion of a gene therapy product is underway, with two patients already transplanted and demonstrating appropriate engraftment.

Dr. John Manis, Director Transfusion Medicine Service, Associate Professor of Pathology, Harvard Medical School, commented: “The approval of gene therapies for sickle cell disease has opened the door to transformative outcomes, but inadequate stem cell collection has significantly delayed manufacturing and prevented some patients from starting treatment. These findings suggest that motixafortide may help overcome this challenge, and with more studies, expand access to potentially life-changing therapies.”

About Sickle Cell Disease
Sickle cell disease, also known as sickle cell anemia, is a severe inherited blood disorder caused by a genetic mutation that leads to misshapen, rigid red blood cells. These cells can obstruct blood flow, causing sudden episodes of severe pain, known as pain crises, and leading to life-threatening complications. Ayrmid is dedicated to advancing therapies that help individuals living with sickle cell disease manage their symptoms and improve their quality of life.

About Ayrmid Ltd. and Gamida Cell
Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge (please see the current full Prescribing Information, including boxed warning, here) and APHEXDA^® (please see the current full Prescribing Information here). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook or Instagram.

Contacts: Media, Investors / Business Development: bd@ayrmid.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Ayrmid Pharma Ltd.

View the original press release on ACCESS Newswire